Although the anti-VEGF antibody bevacizumab showed promise for the treatment of stage IV colon cancer (1) (2) (3) (4) , it failed to improve clinical outcome of patients diagnosed with stage II/III colon cancer when added to adjuvant chemotherapy.
The C-08 protocol conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP) randomly assigned 2710 patients diagnosed with stage II/III colon adenocarcinoma to receive either oxaliplatin-based chemotherapy (mFOL-FOX6) or mFOLFOX6 plus bevacizumab for 12 months (5) . According to the primary endpoint analysis after median follow up of 35.6 months, the addition of bevacizumab to mFOLFOX6 did not result in a statistically significant increase in disease-free survival (hazard ratio [HR] = 0.89; 95% confidence interval [CI] = 0.76 to 1.04; P = .15). Tests for a potential interaction of the effect of bevacizumab with sex, age, and nodal status were not statistically significant. However, mismatch repair (MMR) status was not examined at that time.
We have updated the analysis of C-08 with the inclusion of MMR status and longer follow-up. MMR status was determined by immunohistochemistry (IHC) with mutL homolog 1 (MLH1) and mutS homolog 2 (MSH2) proteins as described by Lindor (6) . Any patients that showed negative staining of one of the two proteins in the tumor cells in the presence of positive staining in the surrounding normal cells were classified as MMR deficient (dMMR), whereas others were classified as MMR proficient (pMMR). These two immunohistochemistry markers provide both a sensitive and specific alternative to microsatellite instability in detecting DNA MMR defects (6).
The C-08 correlative study was conducted with approvals from institutional review boards for NSABP Biospecimen Bank and Biostatistics Center. Informed consent was required for participation. Formalin-fixed paraffin-embedded tumor blocks were available from 2100 of 2710 randomized patients. Patient characteristics of the MMR study subset were not different from the original trial cohort (Supplementary Table 1 , available online). MMR status could be determined in 1993 patients. There were 107 case subjects with either assay failures with no staining in the normal cells or tissue detachment during the staining procedure. There were 252 case subjects (12.6%) classified as dMMR. In the set of patients with known MMR status, 25% were stage II, and median followup was 5.7 years (range = 0.2-7.4 years).
We also examined the V600E BRAF mutation based on its association with dMMR and worse overall survival (7). V600E mutation was determined using a primer extension assay as previously reported (n = 1764) (8) .
Formal statistical tests for marker-bybevacizumab interaction were performed in a Cox regression model including indicator variables for the marker, bevacizumab treatment, and the interaction term for the following variables: age (<65 vs ≥65 years; n = 2159), sex (n = 2159), T stage (high vs low; n = 2145), N stage (N0, N1, N2 with a 2-degree of freedom interaction test; n = 2159), MMR defects defined by two immunohistochemistry markers (MLH1 and MSH2; deficient, proficient; n = 1993), and V600E BRAF mutation (n = 1764) ( died during the same follow-up period (HR = 0.52; 95% CI = 0.29 to 0.94; P = .03) ( Figure 1A ). In contrast, there was no difference in mortality between the control arm and bevacizumab arm in those who were diagnosed with pMMR tumors. One hundred seventy-two of 873 pMMR patients treated with chemotherapy died, whereas 177 of 868 pMMR patients treated with bevacizumab died during the same follow-up period (HR = 1.03; 95% CI = 0.84 to 1.27; P = .78) ( Figure 1B) . For time to recurrence, there was a trend for interaction in the same direction, but it was not statistically significant (P interaction = .08).
Although BRAF did not show statistically significant interaction, because there was an association between MMR status and BRAF mutation (P < .0001), we examined whether a combination of the two markers could further define the subset that benefited from bevacizumab in an exploratory analysis. We found that a small subset of patients (n = 51 with 16 deaths) defined by BRAF mutation and dMMR derived the most benefit, with a hazard ratio of 0.27 (95% CI = 0.08 to 0.94; P = .03) (data not shown).
Because we defined dMMR based on two immunohistochemistry markers (MLH1 and MSH2), we would have misclassified about 25% of hypermutated tumors (with mutations in MLH3, MSH3, MSH6, PMS2, and POLE) as pMMR based on data from The Cancer Genome Atlas Network (9) . It would be important to examine whether patients diagnosed with hypermutated tumors with the mutations in the latter genes also derived statistically significant clinical benefit from bevacizumab.
Because this was a finding from a retrospective analysis without an a priori hypothesis based on a mechanistic study, the results presented should be regarded only as hypothesis generating. According to published exome capture sequencing data from The Cancer Genome Atlas Network, dMMR tumors are hypermutated, with median number of nonsilent mutation of 728 compared with 58 in pMMR or nonhypermutated tumors (9) . Unlike pMMR tumors that are poorly immunogenic, dMMR tumors are highly immunogenic because of the generation of mutated proteins, including those with frame-shift mutations (10, 11) . Therefore, dMMR tumor cells at the micrometastatic sites have to evade attack from the immune system in order to progress. VEGF-A is speculated to be one of the main tumor-derived soluble factors that act as a chemo-attractant for immature myeloid cells from the marrow to the tumor site and suppress dendritic cell maturation, creating an immune suppressive microenvironment (12) (13) (14) (15) . Furthermore, VEGF-A directly induces regulatory T-cell proliferation in tumor-bearing mice through VEGFR-2 (16). Intriguingly, blocking VEGF-A alone was sufficient to inhibit regulatory T-cell accumulation in tumor-bearing mice but not in tumornaive mice (16) . More important, adding bevacizumab to chemotherapy resulted in a substantial reduction in the proportion of regulatory T-cells in the peripheral blood of colon cancer patients (16). Thus we hypothesize that bevacizumab may be particularly effective in dMMR patients because of its disruption of the immunosuppressive microenvironment associated with these hypermutated and highly immunogenic tumors.
In conclusion, our data suggest that there may be a subset of colon cancer patients who may derive significant clinical benefit from the addition of bevacizumab to standard adjuvant chemotherapy. Although only hypothesis generating, this data warrants independent validation in other randomized clinical trials. 
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